M. Kulyk & Associates LLC Purchases 10,368 Shares of Regeneron Pharmaceuticals, Inc. $REGN

M. Kulyk & Associates LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 258.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,373 shares of the biopharmaceutical company’s stock after buying an additional 10,368 shares during the quarter. Regeneron Pharmaceuticals accounts for approximately 1.6% of M. Kulyk & Associates LLC’s holdings, making the stock its 19th biggest holding. M. Kulyk & Associates LLC’s holdings in Regeneron Pharmaceuticals were worth $8,082,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in REGN. Brighton Jones LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $226,000. Oppenheimer Asset Management Inc. raised its position in Regeneron Pharmaceuticals by 32.7% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 2,608 shares of the biopharmaceutical company’s stock valued at $1,369,000 after purchasing an additional 643 shares during the last quarter. Banco Santander S.A. lifted its holdings in Regeneron Pharmaceuticals by 65.0% in the 2nd quarter. Banco Santander S.A. now owns 19,558 shares of the biopharmaceutical company’s stock worth $10,268,000 after buying an additional 7,706 shares during the period. Finally, Y Intercept Hong Kong Ltd grew its position in shares of Regeneron Pharmaceuticals by 259.4% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 34,874 shares of the biopharmaceutical company’s stock worth $18,309,000 after buying an additional 25,170 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.9%

Shares of NASDAQ REGN opened at $787.04 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The stock has a market cap of $83.21 billion, a P/E ratio of 18.94, a price-to-earnings-growth ratio of 2.09 and a beta of 0.40. The firm has a 50-day moving average of $769.67 and a 200 day moving average of $676.28. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the prior year, the company earned $12.07 earnings per share. The business’s revenue was up 2.5% compared to the same quarter last year. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be given a dividend of $0.94 per share. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend is Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.05%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on REGN. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and upped their target price for the company from $627.00 to $860.00 in a report on Wednesday, January 7th. Royal Bank Of Canada upped their price objective on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. Morgan Stanley lifted their target price on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. Oppenheimer reiterated an “outperform” rating and set a $865.00 price target (up previously from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Finally, Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, February 16th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $793.81.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the sale, the director directly owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 5,274 shares of company stock worth $4,142,738 over the last three months. 7.02% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.